ACN Factor-Based Stock Analysis

Validea's guru fundamental report assigns Accenture PLC (ACN), a large-cap computer services firm, an exceptionally high 92% rating on its Warren Buffett-inspired Patient Investor model. This strong endorsement reflects ACN's robust fundamentals, including predictable profitability, low debt, strong free cash flow, and high returns on equity and capital, indicating it meets the criteria for a long-term, value-oriented investment.

Analysis

Accenture PLC (ACN) has received a highly positive evaluation from Validea's guru fundamental report, scoring 92% on its 'Patient Investor' model, which is based on Warren Buffett's investment strategy. A score above 90% signifies strong interest from the model. This high rating is underpinned by ACN's robust fundamentals, as it passed critical tests for earnings predictability, low debt service, and high returns on both equity and total capital. The report also highlights the company's strong free cash flow generation and effective use of retained earnings. According to the model's criteria, ACN's valuation is considered reasonable, passing metrics for both initial and expected rates of return. The only non-passing grade was a 'Neutral' on its share repurchase activity, a minor blemish on an otherwise exceptional fundamental scorecard. The overall assessment, supported by a very high per-ticker sentiment score of 0.85, positions the large-cap computer services firm as a high-quality name that aligns with the principles of long-term, value-oriented investing.

Key Decisions for Investors

• Investors with a long-term, fundamentals-driven approach should view this report as a strong validation of ACN's quality, suggesting it could serve as a core holding within a portfolio.
• Given the positive assessment of its valuation, which passed tests for both initial and expected returns, investors could consider the current price an attractive entry point for a high-quality company.
• While the overall profile is exceptionally strong, investors may wish to monitor the company's capital allocation strategy, particularly regarding its share repurchase program, which was the only criterion rated as neutral.